HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
BioCryst Pharmaceuticals, Inc. (BCRX)
5.435  -0.09  (-1.63%) 07-13 03:59
Open: 5.5468 High: 5.6
Pre.close: 5.525 Low: 5.24
Volume: 5,610,965 Ave vol: 11,387,260
52w High: 6.29 52w Low: 1.38
MA(50): 4.624 MA(200): 3.47
EPS: -0.912 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biocryst.com
Market Cap (M): 959
Shares Out (M): 176
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
Technical analysis
Overall: Neutral
MA: Bullish MACD: Bullish
KDJ: Bearish RSI: Bearish
Target 1: 7.04 Target 2: 8.23
Resist 1: 6.03 Resist 2: 7.04
Support 1: 4.68 Support 2: 3.84
Company key metrics
Revenue per Share: 0.4224
Net Income per Share: -0.942
Cash per Share: 0.9876
Book Value per Share: 0.3309
Price to Sales: 6.628
Price to Book Value: 8.4618
Earnings Yield: -0.3364
Dividend Yield: 0
Debt to Equity: 3.5823
Debt to Assets: 0.7818
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts
Headline news
Tue, 07 Jul 2020
What You Need To Know About BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Investor Composition - Yahoo Finance

Mon, 15 Jun 2020
Hedge Funds Have Never Been This Bullish On BioCryst Pharmaceuticals, Inc. (BCRX) - Yahoo Finance

Wed, 08 Jul 2020
Investors Are Craving More from BioCryst Pharmaceuticals Inc. [BCRX] Stocks: Here is Why - MZP News

Tue, 07 Jul 2020
Gear up for the change! BioCryst Pharmaceuticals Inc. (BCRX) has hit the volume of 4751854 - The InvestChronicle

Tue, 23 Jun 2020
BioCryst Pharmaceuticals Inc. (BCRX) Soars 3.64% on June 23 - Equities.com

Fri, 03 Jul 2020
Should You Take Comfort From Insider Transactions At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)? - Simply Wall St

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.